Supplementary results_detailed. by Pornpan Chalermkitpanit (22110121)

Subjects:

Baseline characteristics of the participants. by Junichi Kushioka (12236447)

“…<div><p>Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. …”

Internal validation by cross-validation. by Junichi Kushioka (12236447)

“…<div><p>Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. …”

<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate.... by Atefeh Sadeghi (21253051)

“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”

Survival function analysis of mortality for Viral load status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Multivariate Cox proportional hazard analysis ratio of patient factors associated with treatment outcomes in HIV care, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Clinic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of treatment Interruption for Viral load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis of viral suppression for BMI status and Treatment Interruption status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Schematic presentation of sampling of population for analysis. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival curve of ART Treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by clinical characteristics <i>among participants in HIV care Facilities in</i> Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of ART treatment interruption and LTFU by demographic characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Demographic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”